THEMATIC REVIEW

Deiodinases: the balance of thyroid hormone

Local control of thyroid hormone action: role of type 2 deiodinase

Graham R Williams and **J H Duncan Bassett**

Molecular Endocrinology Group, Department of Medicine and Medical Research Council Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, Commonwealth Building 7th Floor, Du Cane Road, London W12 0NN, UK

(Correspondence should be addressed to G R Williams; Email: graham.williams@imperial.ac.uk)

Abstract

The thyroid gland predominantly secretes the pro-hormone thyroxine (T_4) that is converted to the active hormone $3,5,3'$-L-triiodothyronine (T_3) in target cells. Conversion of T_4 to T_3 is catalyzed by the type 2 iodothyronine deiodinase enzyme (DIO2), and T_3 action in target tissues is determined by DIO2-regulated local availability of T_3 to its nuclear receptors, TRα and TRβ. Studies of *Dio2* knockout mice have revealed new and important roles for the enzyme during development and in adulthood in diverse tissues including the cochlea, skeleton, brown fat, pituitary, and hypothalamus. In this review, we discuss the molecular mechanisms by which DIO2 controls intracellular T_3 availability and action.

Journal of Endocrinology (2011) **209**, 261–272

Introduction

Thyroid hormones are important homeostatic regulators that act via nuclear thyroid hormone receptors (TRs) in virtually all tissues during development and throughout postnatal life. $3,5,3',5'$-L-tetraiodothyronine (thyroxine, T_4) is a pro-hormone that circulates at a high concentration in peripheral blood relative to the active hormone $3,5,3'$-L-triiodothyronine (T_3). Concentrations of T_4 and T_3 in target tissues are controlled by metabolism; local conversion of T_4 to T_3 is catalyzed by the type 2 iodothyronine deiodinase enzyme (DIO2), while the type 3 enzyme (DIO3) prevents activation of T_4 and inactivates T_3. This pre-receptor control of ligand availability to TRs in target cells is a crucial mechanism that regulates the timing of cellular responses to thyroid hormones in a tissue-specific manner. The physiological importance of this coordinated process has been demonstrated in several organ systems by a series of elegant *in vivo* studies, and in this study, we review recent developments with particular emphasis on the importance of hormone activation mediated by DIO2.

Thyroid physiology

The hypothalamic–pituitary–thyroid axis

Circulating thyroid hormone concentrations are maintained in the euthyroid range by a classical negative feedback loop (Fig. 1). Thyrotropin–releasing hormone (TRH) is synthesized in the hypothalamic para-ventricular nucleus (PVN) and stimulates synthesis and release of TSH from thyrotroph cells in the anterior pituitary gland. TSH in turn acts via the TSH receptor (TSHR) in thyroid follicular cells to stimulate cellular growth and the synthesis and release of T_4 and T_3 into the circulation (Kopp 2001). Thyroid hormone action is mediated in target tissues by TRs, but thyroid hormones also inhibit TRH and TSH synthesis and secretion in the hypothalamus and pituitary to complete a negative feedback loop (Forrest *et al.* 1996b, Nikrodhanond *et al.* 2006). This negative feedback loop maintains circulating thyroid hormones and TSH in a physiological inverse relationship that defines the hypothalamic–pituitary–thyroid (HPT) axis set-point (Bassett & Williams 2008).

Circulating thyroid hormones and uptake into target cells

The thyroid gland predominantly secretes the inactive pro-hormone T_4, as well as small amounts of the physiologically

active thyroid hormone T_3. Both T_4 and T_3 are lipophilic and poorly soluble in water, and over 95% of thyroid hormones are protein bound in the circulation. Thyroxine-binding globulin (TBG), transthyretin, albumin, and several lipoproteins function as the transport proteins for T_4 and T_3 in plasma. Free thyroid hormone levels are thus dependent upon the concentrations and saturations of these proteins. The unbound free T_3 fraction represents 0·3% of the total T_3 concentration in plasma, but because of its higher binding affinity for TBG, the free T_4 fraction represents just 0·02% of the total plasma T_4 concentration. Thus, despite the total T_4 concentration being 50-fold greater than total T_3, the circulating free T_4 concentration is only fourfold higher. T_4 is exclusively synthesized and secreted by thyroid follicular cells, whereas the majority of circulating T_3 is generated in peripheral tissues by enzymatic removal of a $5'$-iodine from T_4. Due to their lipophilic nature, thyroid hormones had been likely to enter target cells by a passive process of diffusion (Friesema *et al.* 2005). In fact, the free hormones enter target cells via an energy-dependent, ATP-requiring, stereospecific, and saturable transport mechanism that is mediated by the monocarboxylate transporter 8 (MCT8; Friesema *et al.* 2003, 2006, Dumitrescu *et al.* 2006), MCT10, and other transporter proteins including OATP1c1, a member of the Na^+–independent organic anion transporter protein (OATP) family (Jansen *et al.* 2005, Heuer 2007, van der Deure *et al.* 2010; Fig. 2). Transport via MCT8, for example, increases uptake of T_4 and T_3 by tenfold (Friesema *et al.* 2003).


Figure 1 Negative feedback regulation of the hypothalamic–pituitary–thyroid axis. The role of DIO2 in negative feedback control of the HPT axis occurs predominantly in thyrotrophs of the anterior pituitary gland. PVN, para-ventricular nucleus; TRH, thyrotropin-releasing hormone; DIO2, type 2 deiodinase enzyme; TRβ2, thyroid hormone receptor β2; T_4, thyroxine; T_3, 3,5,3'-L-triiodothyronine.

Thyroid hormone metabolism

Deiodinase enzymes

The iodothyronine deiodinases are selenocysteine-containing enzymes that metabolize thyroid hormones to active or inactive products (Bianco *et al.* 2002). The type 1 deiodinase enzyme (DIO1) is rather inefficient with an apparent Michaelis constant (K_m) of 10^{-6}–10^{-7} M and catalyzes removal of inner or outer ring iodine atoms in equimolar proportions to generate T_3, reverse T_3 (rT_3), or 3,3'-diiodothyronine (T_2) depending on the substrate. Most of the circulating T_3 is derived from conversion of T_4 to T_3 by the actions of DIO1, which is localized to the plasma membrane and expressed in liver and kidney. Nevertheless, activity of the DIO2 enzyme in skeletal muscle may also contribute to circulating levels of T_3, although its role is controversial and may differ between species (Bianco *et al.* 2002, Maia *et al.* 2005, Bianco & Kim 2006, Heemstra *et al.* 2009b, Larsen 2009). The DIO2 enzyme is considerably more efficient than DIO1, catalyzing only the removal of an outer ring iodine atom from the pro-hormone T_4 with a K_m of 10^{-9} M to generate the physiologically active product T_3. The major role of DIO2 is to control the intracellular T_3 concentration, its availability to the nucleus, and the saturation of the nuclear T_3 receptor in target tissues. Moreover, DIO2 is likely to protect tissues from the detrimental effects of hypothyroidism because its low K_m continues to permit the efficient local conversion of T_4 to T_3. T_4 treatment of cells, in which MCT8 and DIO2 are co-expressed, results in increased T_3 target gene expression (Friesema *et al.* 2006), indicating that thyroid hormone uptake and metabolism coordinately regulate T_3 action. By contrast, the DIO3 enzyme irreversibly inactivates T_3, or prevents T_4 being activated, by catalyzing removal of an inner ring iodine atom with a K_m of 10^{-9} M to generate T_2 or rT_3 respectively. Thus, inactivating DIO3 prevents thyroid hormone access to specific tissues at critical times and reduces TR saturation (Bianco *et al.* 2002, Bianco & Kim 2006).

Control of intracellular T3 availability

The relative activities of DIO2 and DIO3, which have the same K_m values for substrate, consequently regulate intracellular concentrations of T_3 and its availability to the nuclear TR (Bianco *et al.* 2002, Bianco & Kim 2006, St Germain *et al.* 2009). In conjunction with serum-derived T_3, DIO2 and DIO3 are important local modulators of thyroid hormone responsiveness *in vivo*. Expression of both enzymes is regulated in a temporo-spatial and tissue-specific manner, resulting in varying levels of T_3 action in individual tissues at distinct times during development (Bates *et al.* 1999, St Germain *et al.* 2009). Acting together, DIO2 and DIO3 thus control cellular T_3 availability by a mechanism that is largely independent of serum thyroid hormone concentrations (Bianco & Kim 2006).

Figure 2 Regulation of intracellular supplies of T_3 to the nucleus of T_3 target cells. MCT8 and MCT10, monocarboxylate transporters 8 and 10; OATP1C1, organic acid transporter protein-1C1; DIO2 and DIO3, type 2 and 3 deiodinase enzymes; TR, thyroid hormone receptor, RXR, retinoid X receptor; T_4, thyroxine; T_3, 3,5,3′-L-triiodothyronine; rT_3, 3,3′,5′-triiodothyronine; T_2, 3,3′-diiodothyronine.

Thyroid hormone action

Thyroid hormone receptors

Thyroid hormone actions in target cells are ultimately determined by the availability of T_3 to its nuclear receptor (St Germain *et al*. 2009; Fig. 2). TRα and TRβ are members of the steroid/TR superfamily (Sap *et al*. 1986, Weinberger *et al*. 1986). The TRs are ligand-inducible transcription factors that regulate expression of hormone-responsive target genes. In mammals, the *THRA* gene encodes three C-terminal variants of TRα. TRα1 is a functional receptor that binds both DNA and T_3, whereas TRα2 and TRα3 fail to bind T_3 and act as antagonists *in vitro* (Harvey & Williams 2002). A promoter within intron 7 of mouse *Thra* gives rise to two truncated variants, TRΔα1 and TRΔα2, which act as potent dominant-negative antagonists *in vitro*, although their physiological role is unclear (Chassande *et al*. 1997). The *THRB* gene encodes two N-terminal TRβ variants, TRβ1 and TRβ, both of which act as functional receptors. Two further transcripts, TRβ3 and TRΔβ3, have also been described in the rat, but their physiological role is also uncertain (Williams 2000, Harvey *et al*. 2007). TRα1 and TRβ1 are expressed widely, but their relative concentrations differ during development and in adulthood due to tissue-specific and temporo-spatial regulation (Forrest *et al*. 1990). The current understanding is that most T_3 target tissues are either predominantly TRα1 or TRβ1 responsive or lack TR isoform specificity. Expression of TRβ2, however, is markedly restricted. In the hypothalamus and pituitary, it controls the HPT axis feedback loop by mediating the

inhibitory actions of thyroid hormones on TRH and TSH expression (Fig. 1; Abel *et al*. 1999, 2001), while in the cochlea and retina TRβ2 is an important regulator of sensory development (Ng *et al*. 2001, Jones *et al*. 2007).

Developmental control of T_3 action

Unliganded TRs compete with T_3-bound TRs for DNA response elements. They act as potent transcriptional repressors and have been shown to have critical regulatory roles in the development of a number of key tissues (Hashimoto *et al*. 2001, Chassande 2003, Venero *et al*. 2005, Wallis *et al*. 2008). Unoccupied TRs interact with co-repressor proteins, including nuclear receptor co-repressor (NCoR) and the silencing mediator for retinoid and TR (SMRT), which recruit histone deacetylases and maintain a non-permissive closed chromatin structure to inhibit gene transcription. Ligand-bound TRs, however, interact with steroid receptor co-activator 1 (SRC1) and other related co-activators in a hormone-dependent fashion. These co-activator proteins function as histone acetyl transferases, thereby promoting an open nucleosome structure leading to target gene activation. The contrasting chromatin-modifying effects of liganded and unliganded TRs, thus, greatly enhance the magnitude of the transcriptional response to T_3 (Harvey & Williams 2002, Chassande 2003). In addition to the positive stimulatory effects on target gene expression, T_3 also mediates transcriptional repression to inhibit the expression of certain key target genes, including TSH. Although such negative regulatory effects are physiologically critical, the

responsible underlying molecular mechanisms have not been fully characterized (Cheng *et al.* 2010). Although expression of both TRα1 and TRβ1 is widespread, their relative levels of expression differ between tissues during embryogenesis and in postnatal life. Differential control of TRα1 and TRβ1, therefore, provides another mechanism to regulate tissue-specific T$_3$ responses during development and growth (O'Shea *et al.* 2006). Although the free T$_4$ concentration is approximately fourfold greater than free T$_3$, the TR-binding affinity for T$_3$ is 15-fold higher than its affinity for T$_4$ (Lin *et al.* 1990). Thus, T$_4$ acts as a pro-hormone, which must be metabolized to T$_3$ for the mediation of thyroid hormone actions (Bianco & Kim 2006). Taken together, the temporo-spatial and tissue-specific regulated expression of both the DIO2 and the DIO3 enzymes (Bates *et al.* 1999) and the TRα1 and TRβ1 nuclear receptors (Forrest *et al.* 1990) combine to provide a complex but co-ordinated system for fine control of T$_3$ availability and action in individual cell types during development. DIO3 is expressed in fetal tissues and the utero-placental unit where it acts as a barrier that prevents maternal thyroid hormone access to the developing fetus (Wasco *et al.* 2003).

Unliganded TRs are key factors that prevent premature cell differentiation and maintain cell proliferation in order to allow organogenesis to proceed in the developing fetus (Plateroti *et al.* 2001, Flamant *et al.* 2002, Chassande 2003). In mammals, the reciprocally regulated decrease in DIO3 activity and increase in DIO2 activity at birth results in a rapid rise in T$_3$ production (Bates *et al.* 1999). Similar changes have been observed during metamorphosis and hatching in amphibians and birds respectively (Huang *et al.* 2001). An increase in DIO2 expression in target tissues together with a decrease in DIO3 expression results in an increased intracellular T$_3$ concentration, binding of T$_3$ to its nuclear receptor, and initiation of cell differentiation (Campos-Barros *et al.* 2000, Sachs *et al.* 2000, Huang *et al.* 2001, Plateroti *et al.* 2001, Flamant *et al.* 2002, Mai *et al.* 2004, Ng *et al.* 2004). Thus, TRs function as developmental switches that are dependent on the activities of the deiodinases and which regulate the onset of T$_3$ target tissue differentiation during embryogenesis. For example, in the developing embryo, DIO2 has been shown to regulate the pace of endochondral ossification and bone formation (Dentice *et al.* 2005), while activity of DIO2 in developing cartilage is regulated by the morphogen Indian hedgehog and the ubiquitin ligase WSB-1 (Dentice *et al.* 2005). In addition, ubiquitin-mediated degradation of DIO2 has been shown to regulate thyroid hormone activation in several other tissues (Bianco & Larsen 2005, Fekete *et al.* 2007, Sagar *et al.* 2007). In this situation, ubiquitin-mediated proteasomal degradation of DIO2 is increased following exposure to substrate (T$_4$), and this mechanism thus represents a rapid and sensitive posttranslation mechanism to control and limit the DIO2 activity and T$_3$ production (Gereben *et al.* 2000, Steinsapir *et al.* 2000, Zavacki *et al.* 2009).

These considerations are important physiologically and in thyroid disease. In thyroid hormone deficiency, DIO2 expression and activity are increased, whereas its expression and activity are reduced in thyrotoxicosis. By contrast, DIO3 expression is regulated in a reciprocal manner at extremes of thyroid dysfunction. Thus, the ratio of DIO2 and DIO3 activity determines homeostatic control of T$_3$ availability to the nuclear receptor even in thyroid disease. In the brain, the DIO2 activity is increased in response to hypothyroidism (Burmeister *et al.* 1997), whereas activity of DIO3 is markedly reduced (Friedrichsen *et al.* 2003). This response is considered to protect the developing brain from changes in circulating thyroid hormones and to mitigate the severe and detrimental effects of hypothyroidism (Calvo *et al.* 1990, Guadano-Ferraz *et al.* 1999, Heuer 2007). Thus, maintenance of thyroid hormone availability in specific brain regions is critically regulated by reciprocal expression of DIO2 and DIO3 (Tu *et al.* 1997, 1999, Bianco *et al.* 2002, Kester *et al.* 2004).

Dio2 knockout mice

In order to investigate the function of DIO2 *in vivo*, knockout mice deficient in the enzyme were generated and found to have normal fertility (Schneider *et al.* 2001). *Dio2* knockout (D2KO) mice exhibit isolated hypothyroidism in critical tissues that depend on DIO2-catalyzed T$_4$ to T$_3$ conversion to regulate cellular thyroid status. Thus, D2KO mice have an elevated circulating TSH concentration, are unable to sustain a normal body temperature following cold exposure despite a normal circulating T$_3$ concentration, are deaf, and have brittle bones (de Jesus *et al.* 2001, Schneider *et al.* 2001, Ng *et al.* 2004, Bassett *et al.* 2010), suggesting important physiological roles for DIO2 in the pituitary gland and brain, in brown adipose tissue, in the cochlea, and in the skeleton.

Role of DIO2 in regulation of the HPT axis

Analysis of the HPT axis in D2KO mice demonstrated a two- to threefold increase in the circulating TSH concentration, a 27–40% increase in the T$_4$ level accompanied by reduced clearance of T$_4$ from plasma, but a normal T$_3$ (Schneider *et al.* 2001, Christoffolete *et al.* 2007, Galton *et al.* 2007). Serum TSH was suppressed following treatment with T$_3$ but not in response to T$_4$, indicating that D2KO mice have pituitary resistance to feedback regulation by T$_4$ (Schneider *et al.* 2001). Surprisingly, *TRH* mRNA levels in the PVN were not increased in D2KO mice despite their elevated TSH level, suggesting that resistance to T$_4$ suppression results mainly from *Dio2* deficiency in the pituitary rather than the hypothalamus (Rosene *et al.* 2010). Thus, DIO2 is essential for regulation of the HPT axis and enables the pituitary to respond to changes in the circulating T$_4$ level (Fig. 1). In addition, it is important to note that the inactivating DIO3 enzyme is also a key regulator of the HPT axis. Analysis of DIO3-deficient (D3KO) mice indicates that DIO3 plays a key role in the development of the HPT axis set-point. Neonatal D3KO mutants have elevated

circulating thyroid hormone concentrations due to impaired T$_3$ clearance, whereas central hypothyroidism is evident after 2 weeks of age and results from defective TRH and TSH responsiveness in the pituitary and thyroid (Hernandez *et al*. 2006, 2007). New-born D3KO mice display tissue thyrotoxicosis in the brain despite low circulating T$_4$ levels. However, they also have increased DIO2 activity as a result of the low circulating T$_4$ levels, and this is reflected by an increase in the cellular T$_3$ concentration (Hernandez *et al*. 2006). These observations demonstrate a vital role for DIO3 in the determination of thyroid status in peripheral target tissues and indicate the close inverse relationship between DIO2 and DIO3 during maturation of the HPT axis.

Role of DIO2 in the brain

In the brain, DIO2 is expressed in glial cells, third ventricle tanycytes, astrocytes, and some sensory neurons including nuclei within the trigeminal and auditory pathways (Guadano-Ferraz *et al*. 1997, 1999, Tu *et al*. 1997). As discussed earlier, studies in D2KO mice indicated that DIO2 is required for local T$_3$ generation in the pituitary and essential for normal control of the HPT axis (Schneider *et al*. 2001). In addition, neonatal D2KO mice have a 25–50% reduction in tissue T$_3$ concentrations throughout the brain, which is similar to that seen in hypothyroid wild-type littermate mice. The reduced tissue T$_3$ concentration in neonatal D2KO mice does not result from increased T$_3$ degradation, as activity of the inactivating DIO3 enzyme is not altered in any brain regions (Galton *et al*. 2007). Thus, deficiency of DIO2 results in reduced local T$_3$ generation throughout the developing brain. Nevertheless, expressions of the T$_3$-responsive genes *Hairless*, *TrkB*, *Rc3*, and *Srg1* are less susceptible to change in D2KO mice compared with the altered expression observed in thyroid-deficient mice (Galton *et al*. 2007). Thus, despite the markedly increased expression of DIO2 in the newborn brain (Bates *et al*. 1999), D2KO mice have a mild neurological phenotype in comparison with the severe consequences of systemic hypothyroidism. Although T$_3$ availability in neurons is dependent on the DIO2 activity in adjacent glial cells, these surprising data reveal that compensatory mechanisms can mitigate the neurological damage resulting from DIO2 deficiency and also show that alternative sources of T$_3$ can access the brain during development (Galton *et al*. 2007). These compensatory sources are not likely to involve increased transport mediated by MCT8 because the levels of MCT8 expression in the brain are similar in euthyroid, hypothyroid, and D2KO mice (Galton *et al*. 2007). Although D2 expression peaks at important times during development of the brain and is required to generate adequate intracellular concentrations of T$_3$ throughout the brain, it seems that the consequences of DIO2 deficiency during central nervous system development are mitigated by other sources of T$_3$ such as the cerebrospinal fluid (CSF) or serum (Galton *et al*. 2007).

The physiological efficiency of these compensatory sources of T$_3$ was demonstrated following assessment of neurobehavioral function, which revealed only minimal differences between D2KO and wild-type mice following testing of reflexes, locomotion and agility, learning and memory, olfaction, anxiety, and exploration (Galton *et al*. 2007). Interestingly, a recent study was performed in which T$_3$ target gene expression in cerebral cortex was compared between hypothyroid wild-type D2KO and MCT8KO mice (Morte *et al*. 2010). The aim was to investigate whether the source of tissue T$_3$ in brain via local T$_3$ generation (disrupted in D2KO mice) or via transport across the blood–brain barrier (disrupted in MCT8KO mice) elicited differing target gene responses. Little effect on T$_3$ target gene response was seen in MCT8KO mice because a compensatory increase in DIO2 expression was identified which was proposed to mitigate local T$_3$ deficiency. By contrast, in D2KO mice, there was increased expression of T$_3$ target genes normally inhibited by T$_3$, but no effect was seen on genes that are normally positively regulated by T$_3$. In hypothyroid wild-type mice, however, expression of both negatively and positively regulated T$_3$ target genes was affected (Morte *et al*. 2010). Taken together, these intriguing observations suggest that the source of T$_3$ in the brain (locally generated T$_3$ versus T$_3$ transported from serum and CSF) may influence the T$_3$ response elicited.

Role of DIO2 in brown adipose tissue and adaptive thermogenesis

D2KO mice exposed to cold are unable to maintain their body temperature despite the presence of a normal circulating T$_3$ concentration. The mild hypothermia following cold exposure results from impaired energy expenditure in brown adipose tissue that is mitigated by a compensatory shivering response associated with acute weight loss (de Jesus *et al*. 2001). Isolated brown adipocytes from D2KO mice fail to respond normally to adenylyl cyclase activators or noradrenaline resulting in impaired cAMP, oxygen consumption, and mitochondrial uncoupling protein 1 mRNA responses to adrenergic stimulation. These defects are similar to observations in hypothyroidism but are not seen in brown adipocytes obtained from D2KO mice treated with T$_3$ (de Jesus *et al*. 2001). The findings indicate that the cAMP-dependent DIO2 enzyme is required for adrenergic responsiveness and adaptive thermogenesis in brown adipocytes. Further studies, however, revealed a large compensatory increase in brown fat sympathetic stimulation that bypasses the reduced adrenergic responsiveness of D2KO brown adipocytes. The increased sympathetic tone in brown fat induced a marked lipolytic response, which depletes fatty acid stores and results in the defective adaptive thermogenesis and hypothermia observed in D2KO mice (Christoffolete *et al*. 2004). Subsequent studies also showed that bile acids activate DIO2 in brown fat via a cAMP-dependent mechanism involving the G-protein-coupled receptor TGR5, thus identifying a new role for DIO2 in diet-induced thermogenesis as bile acids were also shown to protect mice from diet-induced obesity (Watanabe *et al*. 2006). Accordingly, D2KO mice have greater

susceptibility to diet-induced obesity that may result in part from impaired brown adipose tissue development during embryogenesis (Hall *et al.* 2010) as well as impaired diet-induced thermogenesis.

Role of DIO2 in muscle

Muscle is an important T_3 target tissue, and euthyroidism is required for its efficient function and regeneration. Recent studies in mice have demonstrated that *Dio2* mRNA and activity are expressed in skeletal muscle. Type I slow-twitch fibers displayed fivefold greater Dio2 activity than type II fast-twitch fibers, and hypothyroidism resulted in a threefold induction of activity without changes in mRNA levels (Marsili *et al.* 2010). MyoD is a master regulator of myogenic differentiation and muscle regeneration, and new studies have established that Dio2-mediated generation of T_3 is essential for efficient transcription of MyoD (Dentice *et al.* 2010). Furthermore, the Dio2 activity is present in muscle stem cells and increases during myogenic differentiation. Accordingly, in D2KO mice, myocytes exhibit a hypothyroid phenotype despite normal circulating T_3 levels, the expression of T_3-responsive genes including MyoD is markedly reduced, and muscle regeneration is delayed following injury. In primary myoblasts, a forkhead box transcription factor, FoxO3, has been shown to induce *Dio2* expression and mediate the surge in Dio2 activity necessary to increase the local intracellular T_3 concentration and thereby ensures normal muscle formation and regeneration (Dentice *et al.* 2010). Thus, *Dio2* is essential for skeletal muscle development, function, and repair.

Role of DIO2 in the cochlea

In the cochlea, DIO2 is expressed in periosteal connective tissue surrounding the internal sensory tissues, with enzyme activity peaking at postnatal day P7, a few days prior to the onset of hearing around P14. TR expression, however, is localized to the cochlea sensory epithelium, suggesting that periosteal DIO2 provides a temporo-spatially regulated paracrine supply of T_3 to the sensory epithelium that is necessary for correct timing of cochlea development and maturation (Campos-Barros *et al.* 2000). This hypothesis was supported by findings in D2KO mice, which exhibit delayed differentiation of the auditory sensory epithelium and delayed cochlea development with abnormal formation of the tectorial membrane. The resulting deafness in D2KO mice is similar to that seen in systemic hypothyroidism or in TRβ knockout mice (Forrest *et al.* 1996*a*, Rusch *et al.* 1998, 2001) but occurs despite circulating levels of thyroid hormones that are normally permissive for development of hearing. Treatment of D2KO mice with T_3 ameliorated the phenotype, indicating that DIO2-dependent local generation of T_3 in the surrounding bony labyrinth is essential for development of the cochlea and subsequent auditory function (Ng *et al.* 2004). In this case, the activating DIO2 enzyme functions as a local paracrine amplifier of T_3 action

to regulate sensory development. More recently, DIO3 was also found to be expressed in the cochlea, and D3KO mice were shown to be deaf and have advanced cochlear maturation (Ng *et al.* 2009), indicating that DIO3 normally protects the cochlea from premature T_3-induced differentiation. Thus, development of the cochlea and the onset of normal auditory function require tightly controlled and correctly timed availability of T_3 that is achieved by co-ordinated reciprocal alterations in the expression and activities of DIO2 and DIO3.

Role of DIO2 in the skeleton

It is well known that hypothyroidism causes delayed bone formation and linear growth retardation. Possible roles for DIO1 and DIO2 in the skeleton were first studied in the context of growth. A minor and transient impairment of weight gain was initially reported in male D2KO mice, although linear growth was not determined (Schneider *et al.* 2001). Weight gain and growth, however, were normal in D1KO- and in DIO1-deficient C3H/HeJ mice and in combined C3H/HeJ D2KO mutants with DIO1 and DIO2 deficiency (Berry *et al.* 1993, Schoenmakers *et al.* 1993, Schneider *et al.* 2006, Christoffolete *et al.* 2007). We and others showed that DIO1 is not expressed in bone and cartilage (LeBron *et al.* 1989, Dreher *et al.* 1998, Gouveia *et al.* 2005, Williams *et al.* 2008), indicating that DIO1 does not directly influence T_3 action in bone.

Nevertheless, important roles for DIO2 during skeletogenesis and in adult bone are emerging. The DIO2 activity was demonstrated in the perichondrium surrounding the embryonic chick growth plate where its activity is regulated by the skeletal morphogen SHH (Dentice *et al.* 2005). SHH is secreted by perichondrial cells and acts in growth plate chondrocytes to stimulate ubiquitin-mediated degradation of DIO2. The resulting modulation of thyroid hormone signaling in the growth plate is accompanied by increased PTHrP signaling, which is also seen in hypothyroidism (Stevens *et al.* 2000) and which regulates the pace of chondrocyte differentiation during early skeletogenesis (Dentice *et al.* 2005). Analysis of developing bone from mice at embryonic days E14·5–E18·5 revealed the presence of DIO2 activity (Capelo *et al.* 2008), suggesting that a similar regulatory role for DIO2 in cartilage during early skeletogenesis may occur in the mouse as well as the developing chick (Dentice *et al.* 2005).

There have been conflicting reports regarding the expression and activity of DIO2 in whole bone tissue extracts and in skeletal cells (LeBron *et al.* 1989, Bohme *et al.* 1992, Ballock & Reddi 1994, Dreher *et al.* 1998, Wakita *et al.* 1998, Gouveia *et al.* 2005, Morimura *et al.* 2005, Capelo *et al.* 2008). Using a sensitive and highly specific HPLC-based assay, we demonstrated that specific DIO2 activity is restricted to differentiated osteoblasts but is undetectable in chondrocytes and osteoclasts (Williams *et al.* 2008). The significance of this finding was investigated in D2KO mice (Bassett *et al.* 2010).

There were no differences in linear growth and bone formation between D2KO and wild-type mice, although adult D2KO mice had brittle bones with impaired resistance to fracture. The phenotype was due to reduced osteoblastic bone formation without impairment of osteoclastic bone resorption, which caused a reduced rate of mineral apposition and prolongation of the formation phase of the bone remodeling cycle, thus facilitating an increase in secondary mineralization that resulted in a generalized increase in bone mineralization density (Bassett *et al.* 2010). The T_3 target gene analysis demonstrated cellular T_3 deficiency restricted to osteoblasts, indicating that maintenance of adult bone mineralization and optimal bone strength requires local DIO2-mediated production of T_3 in osteoblasts (Bassett *et al.* 2010).

These findings suggest that the restricted expression of DIO2 in adult bone is necessary to maintain a higher intracellular T_3 concentration in osteoblasts relative to other skeletal cells. As in other tissues, the DIO2 activity in osteoblasts is increased in hypothyroidism and inhibited in hyperthyroidism (Gouveia *et al.* 2005). Thus, DIO2 acts to buffer the effects of altered serum thyroid hormone levels on the skeleton; the adverse effects of T_3 deficiency on bone mineralization may be mitigated by increased DIO2 activity in osteoblasts, while inhibition of DIO2 activity in hyperthyroidism limits the detrimental effects of thyroid hormone excess (Bassett *et al.* 2010). This hypothesis suggests that optimal bone mineralization and strength are maintained over the physiological range of systemic thyroid hormone concentrations by the regulated activity of DIO2 in osteoblasts. Escape from this local feedback mechanism in osteoblasts may account in part for the increased susceptibility to fracture observed in hypothyroidism and thyrotoxicosis (Vestergaard & Mosekilde 2002, Vestergaard *et al.* 2005), suggesting the possibility of DIO2 as a therapeutic target for the treatment of osteoporosis.

A recent human population study has also suggested that DIO2 may influence susceptibility to osteoarthritis. A genome-wide linkage analysis identified an association between the *DIO2* polymorphism rs225014 and the generalized symptomatic osteoarthritis (Meulenbelt *et al.* 2008), although the association was not replicated in a subsequent association study and meta-analysis (Kerkhof *et al.* 2010). Nevertheless, a recent meta-analysis has also identified a possible role for DIO3 in osteoarthritis susceptibility (Meulenbelt *et al.* 2010). Taken together, these new and preliminary findings suggest that deiodinase-regulated T_3 availability in chondrocytes may play an important role in the regulation of cartilage renewal and repair.

Conserved and pivotal role of DIO2 in the control of seasonal reproduction

A series of recent elegant studies, initially in the Japanese quail (*Coturnix japonica*; Yoshimura *et al.* 2003) but also in mammals, have identified a major role for DIO2 in the seasonal control of reproduction. Seasonal time measurement is achieved by sensing of the changing photoperiod in temperate zones. Regulatory sensing of the changing photoperiod and the subsequent gonadal response are localized to the medio-basal hypothalamus (MBH). In subtraction hybridization studies in the Japanese quail, DIO2 expression was found to be induced by light and the MBH tissue T_3 concentration was increased tenfold following long-day exposure compared with short-day exposure (Yoshimura *et al.* 2003). Furthermore, i.c.v. infusion of T_3, like exposure to long-day conditions, stimulated gonadal growth while infusion of long-day-exposed quails with iopanoic acid (a DIO2 inhibitor) prevented testicular growth. These findings demonstrated that DIO2-mediated local conversion of T_4 to T_3 in the MBH in response to light is a key pathway mediating the photoperiodic seasonal reproduction response (Yoshimura *et al.* 2003). Further studies revealed that the photoperiod response is triggered by light-induced expression of TSH in the pars tuberalis, which subsequently stimulates DIO2 expression in ependymal cells of the MBH via a TSHR-mediated pathway coupled to cAMP that results in light-induced LH secretion (Nakao *et al.* 2008). Additional studies have also revealed that reciprocal changes in DIO2 and DIO3 expression are induced in the MBH in response to changes in the photoperiod (Yasuo *et al.* 2005), and thus coordinated regulation of DIO2 and DIO3 expression has the capacity to mediate sensitive and rapid responses to changes in the photoperiod, thereby highlighting the importance of local control of tissue T_3 availability in the MBH for seasonal reproduction. Nevertheless, the precise downstream molecular consequences of increased T_3 production in the MBH still remain to be elucidated. A melatonin-responsive photoperiod response system in various mammals has also been shown to involve TSH and DIO2 (Watanabe *et al.* 2004, Revel *et al.* 2006, Yasuo *et al.* 2006, 2007, Hanon *et al.* 2008, Nakao *et al.* 2008, Ono *et al.* 2008), suggesting that seasonal reproduction in mammals and birds is regulated by similar conserved pathways that lie downstream of the initial light or melatonin photoperiod stimulus (Yoshimura 2010).

Conclusions

In recent years, the importance of controlled intracellular availability of T_3 in target tissues has been appreciated. The vital roles played by DIO2 in development, during the establishment of the HPT axis and in specific tissues including the pituitary gland, brain, brown adipose tissue, cochlea, and bone, have been documented in considerable detail. Yet, much remains and exciting and important discoveries are inevitable. For example, recent studies are identifying new roles for DIO2 in the heart (Wang *et al.* 2010), in skeletal muscle (Grozovsky *et al.* 2009), during inflammation (Kwakkel *et al.* 2009), and in the pituitary in response to specific drug challenges (Rosene *et al.* 2010). Given the

breadth of expression of DIO2 and its response to cellular stress (Gereben *et al.* 2008), it is likely that the functional repertoire for DIO2 will expand. The immediate challenges will be to identify these new roles and to determine whether functions ascribed to DIO2 from animal studies and genetic manipulation have physiological or pathological importance in man. Of importance in this context, a common Thr92Ala polymorphism has been identified in *DIO2* (Peeters *et al.* 2003). Although *in vitro* biochemical studies indicated no difference in the enzymatic properties of the DIO2 Thr and Ala variants (Peeters *et al.* 2003, Canani *et al.* 2005), thyroid and skeletal muscle tissue extracts from Ala/Ala individuals displayed reduced DIO2 activities (Canani *et al.* 2005). The mechanism responsible for reduced tissue activity is not known but may result from linkage disequilibrium between the Thr92Ala polymorphism and a second functional variant elsewhere (Canani *et al.* 2005). Nevertheless, in addition to osteoarthritis (Meulenbelt *et al.* 2008, Kerkhof *et al.* 2010), the Thr92Ala polymorphism has also been associated with variation in the HPT axis (Peeters *et al.* 2005, Butler *et al.* 2010), altered bone turnover (Heemstra *et al.* 2010), variable and contradictory effects on cognitive parameters, and the response to thyroid hormone replacement (Appelhof *et al.* 2005, Torlontano *et al.* 2008, Heemstra *et al.* 2009*a*, Panicker *et al.* 2009), as well as having an inconsistent relationship to hypertension, insulin resistance, and the metabolic syndrome (Mentuccia *et al.* 2002, 2005, Canani *et al.* 2005, 2007, Grarup *et al.* 2007, Gumieniak & Williams 2007, Gumieniak *et al.* 2007, Peeters *et al.* 2007, van der Deure *et al.* 2009, Dora *et al.* 2010, Estivalet *et al.* 2010).

Ultimately, an important challenge will be to exploit DIO2 as a drug target to manipulate tissue thyroid status, perhaps in the treatment of metabolic disorders including obesity or skeletal disorders such as osteoporosis and osteoarthritis.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

References

Abel ED, Boers ME, Pazos-Moura C, Moura E, Kaulbach H, Zakaria M, Lowell B, Radovick S, Liberman MC & Wondisford F 1999 Divergent roles for thyroid hormone receptor beta isoforms in the endocrine axis and auditory system. *Journal of Clinical Investigation* **104** 291–300. (doi:10.1172/JCI6397)

Abel ED, Ahima RS, Boers ME, Elmquist JK & Wondisford FE 2001 Critical role for thyroid hormone receptor beta2 in the regulation of paraventricular thyrotropin-releasing hormone neurons. *Journal of Clinical Investigation* **107** 1017–1023. (doi:10.1172/JCI10858)

Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ & Fliers E 2005 Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. *Journal of Clinical Endocrinology and Metabolism* **90** 6296–6299. (doi:10.1210/jc.2005-0451)

Ballock RT & Reddi AH 1994 Thyroxine is the serum factor that regulates morphogenesis of columnar cartilage from isolated chondrocytes in chemically defined medium. *Journal of Cell Biology* **126** 1311–1318. (doi:10.1083/jcb.126.5.1311)

Bassett JH & Williams GR 2008 Critical role of the hypothalamic–pituitary–thyroid axis in bone. *Bone* **43** 418–426. (doi:10.1016/j.bone.2008.05.007)

Bassett JH, Boyde A, Howell PG, Bassett RH, Galliford TM, Archanco M, Evans H, Lawson MA, Croucher P, St Germain DL *et al.* 2010 Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. *PNAS* **107** 7604–7609. (doi:10.1073/pnas.0911346107)

Bates JM, St Germain DL & Galton VA 1999 Expression profiles of the three iodothyronine deiodinases, D1, D2, and D3, in the developing rat. *Endocrinology* **140** 844–851. (doi:10.1210/en.140.2.844)

Berry MJ, Grieco D, Taylor BA, Maia AL, Kieffer JD, Beamer W, Glover E, Poland A & Larsen PR 1993 Physiological and genetic analyses of inbred mouse strains with a type I iodothyronine 5′ deiodinase deficiency. *Journal of Clinical Investigation* **92** 1517–1528. (doi:10.1172/JCI116730)

Bianco AC & Kim BW 2006 Deiodinases: implications of the local control of thyroid hormone action. *Journal of Clinical Investigation* **116** 2571–2579. (doi:10.1172/JCI29812)

Bianco AC & Larsen PR 2005 Cellular and structural biology of the deiodinases. *Thyroid* **15** 777–786. (doi:10.1089/thy.2005.15.777)

Bianco AC, Salvatore D, Gereben B, Berry MJ & Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. *Endocrine Reviews* **23** 38–89. (doi:10.1210/er.23.1.38)

Bohme K, Conscience-Egli M, Tschan T, Winterhalter KH & Bruckner P 1992 Induction of proliferation or hypertrophy of chondrocytes in serum-free culture: the role of insulin-like growth factor-I, insulin, or thyroxine. *Journal of Cell Biology* **116** 1035–1042. (doi:10.1083/jcb.116.4.1035)

Burmeister LA, Pachucki J & St Germain DL 1997 Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms. *Endocrinology* **138** 5231–5237. (doi:10.1210/en.138.12.5231)

Butler PW, Smith SM, Linderman JD, Brychta RJ, Alberobello AT, Dubaz OM, Luzon JA, Skarulis MC, Cochran CS, Wesley RA *et al.* 2010 The Thr92Ala 5′ type 2 deiodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study. *Thyroid* **20** 1407–1412. (doi:10.1089/thy.2010.0244)

Calvo R, Obregon MJ, Ruiz de Ona C, Escobar del Rey F & Morreale de Escobar G 1990 Congenital hypothyroidism, as studied in rats. Crucial role of maternal thyroxine but not of 3,5,3′-triiodothyronine in the protection of the fetal brain. *Journal of Clinical Investigation* **86** 889–899. (doi:10.1172/JCI114790)

Campos-Barros A, Amma LL, Faris JS, Shailam R, Kelley MW & Forrest D 2000 Type 2 iodothyronine deiodinase expression in the cochlea before the onset of hearing. *PNAS* **97** 1287–1292. (doi:10.1073/pnas.97.3.1287)

Canani LH, Capp C, Dora JM, Meyer EL, Wagner MS, Harney JW, Larsen PR, Gross JL, Bianco AC & Maia AL 2005 The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism* **90** 3472–3478. (doi:10.1210/jc.2004-1977)

Canani LH, Leie MA, Machado WE, Capp C & Maia AL 2007 Type 2 deiodinase Thr92Ala polymorphism is not associated with arterial hypertension in type 2 diabetes mellitus patients. *Hypertension* **49** e47. (doi:10.1161/HYPERTENSIONAHA.107.088278)

Capelo LP, Beber EH, Huang SA, Zorn TM, Bianco AC & Gouveia CH 2008 Deiodinase-mediated thyroid hormone inactivation minimizes thyroid hormone signaling in the early development of fetal skeleton. *Bone* **43** 921–930. (doi:10.1016/j.bone.2008.06.020)

Chassande O 2003 Do unliganded thyroid hormone receptors have physiological functions? *Journal of Molecular Endocrinology* **31** 9–20. (doi:10.1677/jme.0.0310009)

Chassande O, Fraichard A, Gauthier K, Flamant F, Legrand C, Savatier P, Laudet V & Samarut J 1997 Identification of transcripts initiated from an internal promoter in the c-erbA alpha locus that encode inhibitors of retinoic acid receptor-alpha and triiodothyronine receptor activities. *Molecular Endocrinology* **11** 1278–1290. (doi:10.1210/me.11.9.1278)

Cheng SY, Leonard JL & Davis PJ 2010 Molecular aspects of thyroid hormone actions. *Endocrine Reviews* **31** 139–170. (doi:10.1210/er.2009-0007)

Christoffolete MA, Linardi CC, de Jesus L, Ebina KN, Carvalho SD, Ribeiro MO, Rabelo R, Curcio C, Martins L, Kimura ET *et al.* 2004 Mice with targeted disruption of the Dio2 gene have cold-induced overexpression of the uncoupling protein 1 gene but fail to increase brown adipose tissue lipogenesis and adaptive thermogenesis. *Diabetes* **53** 577–584. (doi:10.2337/diabetes.53.3.577)

Christoffolete MA, Arrojo e Drigo R, Gazoni F, Tente SM, Goncalves V, Amorim BS, Larsen PR, Bianco AC & Zavacki AM 2007 Mice with impaired extrathyroidal thyroxine to 3,5,3′-triiodothyronine conversion maintain normal serum 3,5,3′-triiodothyronine concentrations. *Endocrinology* **148** 954–960. (doi:10.1210/en.2006-1042)

Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, Nissim S, Mornon JP, Zavacki AM, Zeold A *et al.* 2005 The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. *Nature Cell Biology* **7** 698–705. (doi:10.1038/ncb1272)

Dentice M, Marsili A, Ambrosio R, Guardiola O, Sibilio A, Paik JH, Minchiotti G, DePinho RA, Fenzi G, Larsen PR *et al.* 2010 The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. *Journal of Clinical Investigation* **120** 4021–4030. (doi:10.1172/JCI43670)

van der Deure WM, Peeters RP, Uitterlinden AG, Hofman A, Breteler MM, Witteman J & Visser TJ 2009 Impact of thyroid function and polymorphisms in the type 2 deiodinase on blood pressure: the Rotterdam Study and the Rotterdam Scan Study. *Clinical Endocrinology* **71** 137–144. (doi:10.1111/j.1365-2265.2008.03447.x)

van der Deure WM, Peeters RP & Visser TJ 2010 Molecular aspects of thyroid hormone transporters, including MCT8, MCT10, and OATPs, and the effects of genetic variation in these transporters. *Journal of Molecular Endocrinology* **44** 1–11. (doi:10.1677/JME-09-0042)

Dora JM, Machado WE, Rheinheimer J, Crispim D & Maia AL 2010 Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case–control study and meta-analysis. *European Journal of Endocrinology* **163** 427–434. (doi:10.1530/EJE-10-0419)

Dreher I, Schutze N, Baur A, Hesse K, Schneider D, Kohrle J & Jakob F 1998 Selenoproteins are expressed in fetal human osteoblast-like cells. *Biochemical and Biophysical Research Communications* **245** 101–107. (doi:10.1006/bbrc.1998.8393)

Dumitrescu AM, Liao XH, Weiss RE, Millen K & Refetoff S 2006 Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (mct) 8-deficient mice. *Endocrinology* **147** 4036–4043. (doi:10.1210/en.2006-0390)

Estivalet AA, Leiria LB, Dora JM, Rheinheimer J, Boucas AP, Maia AL & Crispim D 2010 D2 Thr92Ala and PPARgamma2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients. *Obesity*. (doi:10.1038/oby.2010.231)

Fekete C, Freitas BC, Zeold A, Wittmann G, Kadar A, Liposits Z, Christoffolete MA, Singru P, Lechan RM, Bianco AC *et al.* 2007 Expression patterns of WSB-1 and USP-33 underlie cell-specific posttranslational control of type 2 deiodinase in the rat brain. *Endocrinology* **148** 4865–4874. (doi:10.1210/en.2007-0448)

Flamant F, Poguet AL, Plateroti M, Chassande O, Gauthier K, Streichenberger N, Mansouri A & Samarut J 2002 Congenital hypothyroid Pax8(−/−) mutant mice can be rescued by inactivating the TRalpha gene. *Molecular Endocrinology* **16** 24–32. (doi:10.1210/me.16.1.24)

Forrest D, Sjoberg M & Vennstrom B 1990 Contrasting developmental and tissue-specific expression of alpha and beta thyroid hormone receptor genes. *EMBO Journal* **9** 1519–1528.

Forrest D, Erway LC, Ng L, Altschuler R & Curran T 1996*a* Thyroid hormone receptor beta is essential for development of auditory function. *Nature Genetics* **13** 354–357. (doi:10.1038/ng0796-354)

Forrest D, Hanebuth E, Smeyne RJ, Everds N, Stewart CL, Wehner JM & Curran T 1996*b* Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function. *EMBO Journal* **15** 3006–3015.

Friedrichsen S, Christ S, Heuer H, Schafer MK, Mansouri A, Bauer K & Visser TJ 2003 Regulation of iodothyronine deiodinases in the Pax8−/− mouse model of congenital hypothyroidism. *Endocrinology* **144** 777–784. (doi:10.1210/en.2002-220715)

Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP & Visser TJ 2003 Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. *Journal of Biological Chemistry* **278** 40128–40135. (doi:10.1074/jbc.M300909200)

Friesema EC, Jansen J, Milici C & Visser TJ 2005 Thyroid hormone transporters. *Vitamins and Hormones* **70** 137–167. (doi:10.1016/S0083-6729(05)70005-4)

Friesema EC, Kuiper GG, Jansen J, Visser TJ & Kester MH 2006 Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism. *Molecular Endocrinology* **20** 2761–2772. (doi:10.1210/me.2005-0256)

Galton VA, Wood ET, St Germain EA, Withrow CA, Aldrich G, St Germain GM, Clark AS & St Germain DL 2007 Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development. *Endocrinology* **148** 3080–3088. (doi:10.1210/en.2006-1727)

Gereben B, Goncalves C, Harney JW, Larsen PR & Bianco AC 2000 Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. *Molecular Endocrinology* **14** 1697–1708. (doi:10.1210/me.14.11.1697)

Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeold A & Bianco AC 2008 Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. *Endocrine Reviews* **29** 898–938. (doi:10.1210/er.2008-0019)

Gouveia CH, Christoffolete MA, Zaitune CR, Dora JM, Harney JW, Maia AL & Bianco AC 2005 Type 2 iodothyronine selenodeiodinase is expressed throughout the mouse skeleton and in the MC3T3-E1 mouse osteoblastic cell line during differentiation. *Endocrinology* **146** 195–200. (doi:10.1210/en.2004-1043)

Grarup N, Andersen MK, Andreasen CH, Albrechtsen A, Borch-Johnsen K, Jorgensen T, Auwerx J, Schmitz O, Hansen T & Pedersen O 2007 Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. *Journal of Clinical Endocrinology and Metabolism* **92** 363–366. (doi:10.1210/jc.2006-1958)

Grozovsky R, Ribich S, Rosene ML, Mulcahey MA, Huang SA, Patti ME, Bianco AC & Kim BW 2009 Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. *Endocrinology* **150** 1976–1983. (doi:10.1210/en.2008-0938)

Guadano-Ferraz A, Obregon MJ, St Germain DL & Bernal J 1997 The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. *PNAS* **94** 10391–10396. (doi:10.1073/pnas.94.19.10391)

Guadano-Ferraz A, Escamez MJ, Rausell E & Bernal J 1999 Expression of type 2 iodothyronine deiodinase in hypothyroid rat brain indicates an important role of thyroid hormone in the development of specific primary sensory systems. *Journal of Neuroscience* **19** 3430–3439.

Gumieniak O & Williams GH 2007 Response to type 2 deiodinase Thr92Ala polymorphism is not associated with arterial hypertension in type 2 diabetes mellitus patients. *Hypertension* **49** e48. (doi:10.1161/HYPERTENSIONAHA.107.088559)

Gumieniak O, Perlstein TS, Williams JS, Hopkins PN, Brown NJ, Raby BA & Williams GH 2007 Ala92 type 2 deiodinase allele increases risk for the development of hypertension. *Hypertension* **49** 461–466. (doi:10.1161/01.HYP.0000256295.72185.fd)

Hall JA, Ribich S, Christoffolete MA, Simovic G, Correa-Medina M, Patti ME & Bianco AC 2010 Absence of thyroid hormone activation during development underlies a permanent defect in adaptive thermogenesis. *Endocrinology* **151** 4573–4582. (doi:10.1210/en.2010-0511)

Hanon EA, Lincoln GA, Fustin JM, Dardente H, Masson-Pevet M, Morgan PJ & Hazlerigg DG 2008 Ancestral TSH mechanism signals summer in a photoperiodic mammal. *Current Biology* **18** 1147–1152. (doi:10.1016/j.cub.2008.06.076)

Harvey CB & Williams GR 2002 Mechanism of thyroid hormone action. *Thyroid* **12** 441–446. (doi:10.1089/105072502760143791)

Harvey CB, Bassett JH, Maruvada P, Yen PM & Williams GR 2007 The rat thyroid hormone receptor (TR) Deltabeta3 displays cell-, TR isoform-, and thyroid hormone response element-specific actions. *Endocrinology* **148** 1764–1773. (doi:10.1210/en.2006-1248)

Hashimoto K, Curty FH, Borges PP, Lee CE, Abel ED, Elmquist JK, Cohen RN & Wondisford FE 2001 An unliganded thyroid hormone receptor causes severe neurological dysfunction. *PNAS* **98** 3998–4003. (doi:10.1073/pnas.051454698)

Heemstra KA, Hoftijzer HC, van der Deure WM, Peeters RP, Fliers E, Appelhof BC, Wiersinga WM, Corssmit EP, Visser TJ & Smit JW 2009*a* Thr92Ala polymorphism in the type 2 deiodinase is not associated with T₄ dose in athyroid patients or patients with Hashimoto thyroiditis. *Clinical Endocrinology* **71** 279–283. (doi:10.1111/j.1365-2265.2008.03474.x)

Heemstra KA, Soeters MR, Fliers E, Serlie MJ, Burggraaf J, van Doorn MB, van der Klaauw AA, Romijn JA, Smit JW, Corssmit EP *et al.* 2009*b* Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting. *Journal of Clinical Endocrinology and Metabolism* **94** 2144–2150. (doi:10.1210/jc.2008-2520)

Heemstra KA, Hoftijzer H, van der Deure WM, Peeters RP, Hamdy NA, Pereira A, Corssmit EP, Romijn JA, Visser TJ & Smit JW 2010 The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. *Journal of Bone and Mineral Research* **25** 1385–1391. (doi:10.1002/jbmr.27)

Hernandez A, Martinez ME, Fiering S, Galton VA & St Germain D 2006 Type 3 deiodinase is critical for the maturation and function of the thyroid axis. *Journal of Clinical Investigation* **116** 476–484. (doi:10.1172/JCI26240)

Hernandez A, Martinez ME, Liao XH, Van Sande J, Refetoff S, Galton VA & St Germain DL 2007 Type 3 deiodinase deficiency results in functional abnormalities at multiple levels of the thyroid axis. *Endocrinology* **148** 5680–5687. (doi:10.1210/en.2007-0652)

Heuer H 2007 The importance of thyroid hormone transporters for brain development and function. *Best Practice and Research. Clinical Endocrinology and Metabolism* **21** 265–276. (doi:10.1016/j.beem.2007.03.003)

Huang H, Cai L, Remo BF & Brown DD 2001 Timing of metamorphosis and the onset of the negative feedback loop between the thyroid gland and the pituitary is controlled by type II iodothyronine deiodinase in *Xenopus laevis*. *PNAS* **98** 7348–7353. (doi:10.1073/pnas.131198998)

Jansen J, Friesema EC, Milici C & Visser TJ 2005 Thyroid hormone transporters in health and disease. *Thyroid* **15** 757–768. (doi:10.1089/thy.2005.15.757)

de Jesus LA, Carvalho SD, Ribeiro MO, Schneider M, Kim SW, Harney JW, Larsen PR & Bianco AC 2001 The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. *Journal of Clinical Investigation* **108** 1379–1385.

Jones I, Ng L, Liu H & Forrest D 2007 An intron control region differentially regulates expression of thyroid hormone receptor beta2 in the cochlea, pituitary, and cone photoreceptors. *Molecular Endocrinology* **21** 1108–1119. (doi:10.1210/me.2007-0037)

Kerkhof HJ, Lories RJ, Meulenbelt I, Jonsdottir I, Valdes AM, Arp P, Ingvarsson T, Jhamai M, Jonsson H, Stolk L *et al.* 2010 A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. *Arthritis and Rheumatism* **62** 499–510. (doi:10.1002/art.27184)

Kester MH, Martinez de Mena R, Obregon MJ, Marinkovic D, Howatson A, Visser TJ, Hume R & Morreale de Escobar G 2004 Iodothyronine levels in the human developing brain: major regulatory roles of iodothyronine deiodinases in different areas. *Journal of Clinical Endocrinology and Metabolism* **89** 3117–3128. (doi:10.1210/jc.2003-031832)

Kopp P 2001 The TSH receptor and its role in thyroid disease. *Cellular and Molecular Life Sciences* **58** 1301–1322. (doi:10.1007/PL00000941)

Kwakkel J, van Beeren HC, Ackermans MT, Platvoet-Ter Schiphorst MC, Fliers E, Wiersinga WM & Boelen A 2009 Skeletal muscle deiodinase type 2 regulation during illness in mice. *Journal of Endocrinology* **203** 263–270. (doi:10.1677/JOE-09-0118)

Larsen PR 2009 Type 2 iodothyronine deiodinase in human skeletal muscle: new insights into its physiological role and regulation. *Journal of Clinical Endocrinology and Metabolism* **94** 1893–1895. (doi:10.1210/jc.2009-0791)

LeBron BA, Pekary AE, Mirell C, Hahn TJ & Hershman JM 1989 Thyroid hormone 5′-deiodinase activity, nuclear binding, and effects on mitogenesis in UMR-106 osteoblastic osteosarcoma cells. *Journal of Bone and Mineral Research* **4** 173–178. (doi:10.1002/jbmr.5650040207)

Lin KH, Fukuda T & Cheng SY 1990 Hormone and DNA binding activity of a purified human thyroid hormone nuclear receptor expressed in *Escherichia coli*. *Journal of Biological Chemistry* **265** 5161–5165.

Mai W, Janier MF, Allioli N, Quignodon L, Chuzel T, Flamant F & Samarut J 2004 Thyroid hormone receptor alpha is a molecular switch of cardiac function between fetal and postnatal life. *PNAS* **101** 10332–10337. (doi:10.1073/pnas.0401843101)

Maia AL, Kim BW, Huang SA, Harney JW & Larsen PR 2005 Type 2 iodothyronine deiodinase is the major source of plasma T₃ in euthyroid humans. *Journal of Clinical Investigation* **115** 2524–2533. (doi:10.1172/JCI25083)

Marsili A, Ramadan W, Harney JW, Mulcahey M, Castroneves LA, Goemann IM, Wajner SM, Huang SA, Zavacki AM, Maia AL *et al.* 2010 Type 2 iodothyronine deiodinase levels are higher in slow-twitch than fast-twitch mouse skeletal muscle and are increased in hypothyroidism. *Endocrinology* **151** 5952–5960. (doi:10.1210/en.2010-0631)

Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR & Celi FS 2002 Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. *Diabetes* **51** 880–883. (doi:10.2337/diabetes.51.3.880)

Mentuccia D, Thomas MJ, Coppotelli G, Reinhart LJ, Mitchell BD, Shuldiner AR & Celi FS 2005 The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. *Thyroid* **15** 1223–1227. (doi:10.1089/thy.2005.15.1223)

Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ, van der Wijk HJ, Kroon HM, Nakajima M, Ikegawa S, Uitterlinden AG *et al.* 2008 Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. *Human Molecular Genetics* **17** 1867–1875. (doi:10.1093/hmg/ddn082)

Meulenbelt I, Bos SD, Chapman K, van der Breggen R, Houwing-Duistermaat JJ, Kremer D, Kloppenburg M, Carr A, Tsezou A, Gonzalez A *et al.* 2010 Meta-analyses of genes modulating intracellular T₃ bio-availability reveal a possible role for the DIO3 gene in osteoarthritis susceptibility. *Annals of Rheumatic Disease* **70** 164–167. (doi:10.1136/ard.2010.133660)

Morimura T, Tsunekawa K, Kasahara T, Seki K, Ogiwara T, Mori M & Murakami M 2005 Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. *Endocrinology* **146** 2077–2084. (doi:10.1210/en.2004-1432)

Morte B, Ceballos A, Diez D, Grijota-Martinez C, Dumitrescu AM, Di Cosmo C, Galton VA, Refetoff S & Bernal J 2010 Thyroid hormone-regulated mouse cerebral cortex genes are differentially dependent on the source of the hormone: a study in monocarboxylate transporter-8- and deiodinase-2-deficient mice. *Endocrinology* **151** 2381–2387. (doi:10.1210/en.2009-0944)

Nakao N, Ono H, Yamamura T, Anraku T, Takagi T, Higashi K, Yasuo S, Katou Y, Kageyama S, Uno Y *et al.* 2008 Thyrotrophin in the pars tuberalis triggers photoperiodic response. *Nature* **452** 317–322. (doi:10.1038/nature06738)

Ng L, Hurley JB, Dierks B, Srinivas M, Salto C, Vennstrom B, Reh TA & Forrest D 2001 A thyroid hormone receptor that is required for the development of green cone photoreceptors. *Nature Genetics* **27** 94–98. (doi:10.1038/83829)

Ng L, Goodyear RJ, Woods CA, Schneider MJ, Diamond E, Richardson GP, Kelley MW, Germain DL, Galton VA & Forrest D 2004 Hearing loss and retarded cochlear development in mice lacking type 2 iodothyronine deiodinase. *PNAS* **101** 3474–3479. (doi:10.1073/pnas.0307402101)

Ng L, Hernandez A, He W, Ren T, Srinivas M, Ma M, Galton VA, St Germain DL & Forrest D 2009 A protective role for type 3 deiodinase, a thyroid hormone-inactivating enzyme, in cochlear development and auditory function. *Endocrinology* **150** 1952–1960. (doi:10.1210/en.2008-1419)

Nikrodhanond AA, Ortiga-Carvalho TM, Shibusawa N, Hashimoto K, Liao XH, Refetoff S, Yamada M, Mori M & Wondisford FE 2006 Dominant role of thyrotropin-releasing hormone in the hypothalamic–pituitary–thyroid axis. *Journal of Biological Chemistry* **281** 5000–5007. (doi:10.1074/jbc.M511530200)

Ono H, Hoshino Y, Yasuo S, Watanabe M, Nakane Y, Murai A, Ebihara S, Korf HW & Yoshimura T 2008 Involvement of thyrotropin in photoperiodic signal transduction in mice. *PNAS* **105** 18238–18242. (doi:10.1073/pnas.0808952105)

O'Shea PJ, Bassett JH, Cheng SY & Williams GR 2006 Characterization of skeletal phenotypes of TRalpha1 and TRbeta mutant mice: implications for tissue thyroid status and T₃ target gene expression. *Nuclear Receptor Signaling* **4** e011.

Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM & Dayan CM 2009 Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. *Journal of Clinical Endocrinology and Metabolism* **94** 1623–1629. (doi:10.1210/jc.2008-1301)

Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG & Visser TJ 2003 Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. *Journal of Clinical Endocrinology and Metabolism* **88** 2880–2888. (doi:10.1210/jc.2002-021592)

Peeters RP, van den Beld AW, Attalki H, Toor H, de Rijke YB, Kuiper GG, Lambers SW, Janssen JA, Uitterlinden AG & Visser TJ 2005 A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. *American Journal of Physiology. Endocrinology and Metabolism* **289** E75–E81. (doi:10.1152/ajpendo.00571.2004)

Peeters RP, van der Deure WM, van den Beld AW, van Toor H, Lamberts SW, Janssen JA, Uitterlinden AG & Visser TJ 2007 The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men. *Clinical Endocrinology* **66** 808–815. (doi:10.1111/j.1365-2265.2007.02817.x)

Plateroti M, Gauthier K, Domon-Dell C, Freund JN, Samarut J & Chassande O 2001 Functional interference between thyroid hormone receptor alpha (TRalpha) and natural truncated TRDeltaalpha isoforms in the control of intestine development. *Molecular and Cellular Biology* **21** 4761–4772. (doi:10.1128/MCB.21.14.4761-4772.2001)

Revel FG, Saboureau M, Pevet P, Mikkelsen JD & Simonneaux V 2006 Melatonin regulates type 2 deiodinase gene expression in the Syrian hamster. *Endocrinology* **147** 4680–4687. (doi:10.1210/en.2006-0606)

Rosene ML, Wittmann G, Arrojo EDR, Singru PS, Lechan RM & Bianco AC 2010 Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment. *Endocrinology* **151** 5961–5970. (doi:10.1210/en.2010-0553)

Rusch A, Erway LC, Oliver D, Vennstrom B & Forrest D 1998 Thyroid hormone receptor beta-dependent expression of a potassium conductance in inner hair cells at the onset of hearing. *PNAS* **95** 15758–15762. (doi:10.1073/pnas.95.26.15758)

Rusch A, Ng L, Goodyear R, Oliver D, Lisoukov I, Vennstrom B, Richardson G, Kelley MW & Forrest D 2001 Retardation of cochlear maturation and impaired hair cell function caused by deletion of all known thyroid hormone receptors. *Journal of Neuroscience* **21** 9792–9800.

Sachs LM, Damjanovski S, Jones PL, Li Q, Amano T, Ueda S, Shi YB & Ishizuya-Oka A 2000 Dual functions of thyroid hormone receptors during *Xenopus* development. *Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology* **126** 199–211. (doi:10.1016/S0305-0491(00)00198-X)

Sagar GD, Gereben B, Callebaut I, Mornon JP, Zeold A, da Silva WS, Luongo C, Dentice M, Tente SM, Freitas BC *et al.* 2007 Ubiquitination-induced conformational change within the deiodinase dimer is a switch regulating enzyme activity. *Molecular and Cellular Biology* **27** 4774–4783. (doi:10.1128/MCB.00283-07)

Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, Beug H & Vennstrom B 1986 The c-erb-A protein is a high-affinity receptor for thyroid hormone. *Nature* **324** 635–640. (doi:10.1038/324635a0)

Schneider MJ, Fiering SN, Pallud SE, Parlow AF, St Germain DL & Galton VA 2001 Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T₄. *Molecular Endocrinology* **15** 2137–2148. (doi:10.1210/me.15.12.2137)

Schneider MJ, Fiering SN, Thai B, Wu SY, St Germain E, Parlow AF, St Germain DL & Galton VA 2006 Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. *Endocrinology* **147** 580–589. (doi:10.1210/en.2005-0739)

Schoenmakers CH, Pigmans IG, Poland A & Visser TJ 1993 Impairment of the selenoenzyme type I iodothyronine deiodinase in C3H/He mice. *Endocrinology* **132** 357–361. (doi:10.1210/en.132.1.357)

Steinsapir J, Bianco AC, Buettner C, Harney J & Larsen PR 2000 Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center. *Endocrinology* **141** 1127–1135. (doi:10.1210/en.141.3.1127)

Stevens DA, Hasserjian RP, Robson H, Siebler T, Shalet SM & Williams GR 2000 Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation. *Journal of Bone and Mineral Research* **15** 2431–2442. (doi:10.1359/jbmr.2000.15.12.2431)

St Germain DL, Galton VA & Hernandez A 2009 Minireview: defining the roles of the iodothyronine deiodinases: current concepts and challenges. *Endocrinology* **150** 1097–1107. (doi:10.1210/en.2008-1588)

Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R *et al.* 2008 Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. *Journal of Clinical Endocrinology and Metabolism* **93** 910–913. (doi:10.1210/jc.2007-1067)

Tu HM, Kim SW, Salvatore D, Bartha T, Legradi G, Larsen PR & Lechan RM 1997 Regional distribution of type 2 thyroxine deiodinase messenger ribonucleic acid in rat hypothalamus and pituitary and its regulation by thyroid hormone. *Endocrinology* **138** 3359–3368. (doi:10.1210/en.138.8.3359)

Tu HM, Legradi G, Bartha T, Salvatore D, Lechan RM & Larsen PR 1999 Regional expression of the type 3 iodothyronine deiodinase messenger ribonucleic acid in the rat central nervous system and its regulation by thyroid hormone. *Endocrinology* **140** 784–790. (doi:10.1210/en.140.2.784)

Venero C, Guadano-Ferraz A, Herrero AI, Nordstrom K, Manzano J, de Escobar GM, Bernal J & Vennstrom B 2005 Anxiety, memory impairment, and locomotor dysfunction caused by a mutant thyroid hormone receptor alpha1 can be ameliorated by T₃ treatment. *Genes and Development* **19** 2152–2163. (doi:10.1101/gad.346105)

Vestergaard P & Mosekilde L 2002 Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. *Thyroid* **12** 411–419. (doi:10.1089/105072502760043503)

Vestergaard P, Rejnmark L & Mosekilde L 2005 Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. *Calcified Tissue International* **77** 139–144. (doi:10.1007/s00223-005-0068-x)

Wakita R, Izumi T & Itoman M 1998 Thyroid hormone-induced chondrocyte terminal differentiation in rat femur organ culture. *Cell Tissue Research* **293** 357–364. (doi:10.1007/s004410051127)

Wallis K, Sjogren M, van Hogerlinden M, Silberg G, Fisahn A, Nordstrom K, Larsson L, Westerblad H, Morreale de Escobar G, Shupliakov O *et al.* 2008 Locomotor deficiencies and aberrant development of subtype-specific

GABAergic interneurons caused by an unliganded thyroid hormone receptor alpha1. *Journal of Neuroscience* **28** 1904–1915. (doi:10.1523/JNEUROSCI.5163-07.2008)

Wang YY, Morimoto S, Du CK, Lu QW, Zhan DY, Tsutsumi T, Ide T, Miwa Y, Takahashi-Yanaga F & Sasaguri T 2010 Up-regulation of type 2 iodothyronine deiodinase in dilated cardiomyopathy. *Cardiovascular Research* **87** 636–646. (doi:10.1093/cvr/cvq133)

Wasco EC, Martinez E, Grant KS, St Germain EA, St Germain DL & Galton VA 2003 Determinants of iodothyronine deiodinase activities in rodent uterus. *Endocrinology* **144** 4253–4261. (doi:10.1210/en.2003-0490)

Watanabe M, Yasuo S, Watanabe T, Yamamura T, Nakao N, Ebihara S & Yoshimura T 2004 Photoperiodic regulation of type 2 deiodinase gene in Djungarian hamster: possible homologies between avian and mammalian photoperiodic regulation of reproduction. *Endocrinology* **145** 1546–1549. (doi:10.1210/en.2003-1593)

Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T *et al.* 2006 Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* **439** 484–489. (doi:10.1038/nature04330)

Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ & Evans RM 1986 The c-erb-A gene encodes a thyroid hormone receptor. *Nature* **324** 641–646. (doi:10.1038/324641a0)

Williams GR 2000 Cloning and characterization of two novel thyroid hormone receptor beta isoforms. *Molecular and Cellular Biology* **20** 8329–8342. (doi:10.1128/MCB.20.22.8329-8342.2000)

Williams AJ, Robson H, Kester MH, van Leeuwen JP, Shalet SM, Visser TJ & Williams GR 2008 Iodothyronine deiodinase enzyme activities in bone. *Bone* **43** 126–134. (doi:10.1016/j.bone.2008.03.019)

Yasuo S, Watanabe M, Nakao N, Takagi T, Follett BK, Ebihara S & Yoshimura T 2005 The reciprocal switching of two thyroid hormone-activating and -inactivating enzyme genes is involved in the photoperiodic gonadal response of Japanese quail. *Endocrinology* **146** 2551–2554. (doi:10.1210/en.2005-0057)

Yasuo S, Nakao N, Ohkura S, Iigo M, Hagiwara S, Goto A, Ando H, Yamamura T, Watanabe M, Watanabe T *et al.* 2006 Long-day suppressed expression of type 2 deiodinase gene in the mediobasal hypothalamus of the Saanen goat, a short-day breeder: implication for seasonal window of thyroid hormone action on reproductive neuroendocrine axis. *Endocrinology* **147** 432–440. (doi:10.1210/en.2005-0507)

Yasuo S, Watanabe M, Iigo M, Nakamura TJ, Watanabe T, Takagi T, Ono H, Ebihara S & Yoshimura T 2007 Differential response of type 2 deiodinase gene expression to photoperiod between photoperiodic Fischer 344 and nonphotoperiodic Wistar rats. *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology* **292** R1315–R1319. (doi:10.1152/ajpregu.00396.2006)

Yoshimura T 2010 Neuroendocrine mechanism of seasonal reproduction in birds and mammals. *Animal Science Journal* **81** 403–410. (doi:10.1111/j.1740-0929.2010.00777.x)

Yoshimura T, Yasuo S, Watanabe M, Iigo M, Yamamura T, Hirunagi K & Ebihara S 2003 Light-induced hormone conversion of T₄ to T₃ regulates photoperiodic response of gonads in birds. *Nature* **426** 178–181. (doi:10.1038/nature02117)

Zavacki AM, Arrojo EDR, Freitas BC, Chung M, Harney JW, Egri P, Wittmann G, Fekete C, Gereben B & Bianco AC 2009 The E3 ubiquitin ligase TEB4 mediates degradation of type 2 iodothyronine deiodinase. *Molecular and Cellular Biology* **29** 5339–5347. (doi:10.1128/MCB.01498-08)